|
1
|
Yin K, Liao Q, He H and Zhong D:
Prognostic value of Twist and E-cadherin in patients with
osteosarcoma. Med Oncol. 29:3449–3455. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mullen JT, Hornicek FJ, Harmon DC, et al:
Prognostic significance of treatment-induced pathologic necrosis in
extremity and truncal soft tissue sarcoma after neoadjuvant
chemoradiotherapy. Cancer. 120:3676–3682. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou Y, Zang X, Huang Z and Zhang C: TWIST
interacts with endothelin-1/endothelin A receptor signaling in
osteosarcoma cell survival against cisplatin. Oncol Lett.
5:857–861. 2013.PubMed/NCBI
|
|
4
|
Levens D and Larson DR: A new twist on
transcriptional bursting. Cell. 158:241–242. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khan MA, Chen HC, Zhang D and Fu J: Twist:
A molecular target in cancer therapeutics. Tumour Biol.
34:2497–2506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mironchik Y, Winnard PT Jr, Vesuna F, et
al: Twist overexpression induces in vivo angiogenesis and
correlates with chromosomal instability in breast cancer. Cancer
Res. 65:10801–10809. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niu RF, Zhang L, Xi GM, et al:
Up-regulation of Twist induces angiogenesis and correlates with
metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res.
26:385–394. 2007.PubMed/NCBI
|
|
8
|
Wallerand H, Robert G, Pasticier G, et al:
The epithelial-mesenchymal transition-inducing factor TWIST is an
attractive target in advanced and/or metastatic bladder and
prostate cancers. Urol Oncol. 28:473–479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sossey-Alaoui K, Pluskota E, Davuluri G,
et al: Kindlin-3 enhances breast cancer progression and metastasis
by activating Twist-mediated angiogenesis. FASEB J. 28:2260–2271.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Low-Marchelli JM, Ardi VC, Vizcarra EA,
van Rooijen N, Quigley JP and Yang J: Twist1 induces CCL2 and
recruits macrophages to promote angiogenesis. Cancer Res.
73:662–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tanaka T, Yui Y, Naka N, et al: Dynamic
analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a
candidate for anti-metastasis therapy. Clin Exp Metastasis.
30:369–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sakurai T, Okumura H, Matsumoto M, et al:
Endoglin (CD105) is a useful marker for evaluating microvessel
density and predicting prognosis in esophageal squamous cell
carcinoma. Anticancer Res. 34:3431–3438. 2014.PubMed/NCBI
|
|
13
|
Wang WQ, Liu L, Xu HX, et al: The
combination of HTATIP2 expression and microvessel density predicts
converse survival of hepatocellular carcinoma with or without
sorafenib. Oncotarget. 5:3895–3906. 2014.PubMed/NCBI
|
|
14
|
Ek ET, Ojaimi J, Kitagawa Y and Choong PF:
Does the degree of intratumoural microvessel density and VEGF
expression have prognostic significance in osteosarcoma. Oncol Rep.
16:17–23. 2006.PubMed/NCBI
|
|
15
|
He S, Xiao Z, Chen L and Xiong S: Comment
on, Xu XW, et al: Prognostic significance of VEGF expression
in osteosarcoma: A meta-analysis. Tumour Biol. 35:6193–6194. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Becker RG, Galia CR, Morini S and Viana
CR: Immunohistochemical expression of vegf and her-2 proteins in
osteosarcoma biopsies. Acta Ortop Bras. 21:233–238. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ohba T, Cates JM, Cole HA, et al:
Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells
associates with aggressive osteosarcoma. Mol Cancer Res.
12:1100–1111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roberts CC, Daffner RH, Weissman BN, et
al: ACR appropriateness criteria on metastatic bone disease. J Am
Coll Radiol. 7:400–409. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou W, Hao M, Du X, Chen K, Wang G and
Yang J: Advances in targeted therapy for osteosarcoma. Discov Med.
17:301–307. 2014.PubMed/NCBI
|
|
20
|
Rettew AN, Getty PJ and Greenfield EM:
Receptor tyrosine kinases in osteosarcoma: not just the usual
suspects. Adv Exp Med Biol. 804:47–66. 2014.PubMed/NCBI
|
|
21
|
Ohba K, Miyata Y, Matsuo T, et al: High
expression of Twist is associated with tumor aggressiveness and
poor prognosis in patients with renal cell carcinoma. Int J Clin
Exp Pathol. 7:3158–3165. 2014.PubMed/NCBI
|
|
22
|
Galvan JA, Helbling M, Koelzer VH, et al:
TWIST1 and TWIST2 promoter methylation and protein expression in
tumor stroma influence the epithelial-mesenchymal transition-like
tumor budding phenotype in colorectal cancer. Oncotarget.
6:874–885. 2015.PubMed/NCBI
|
|
23
|
Wang T, Li Y, Wang W, et al: Twist2, the
key Twist isoform related to prognosis, promotes invasion of
cervical cancer by inducing epithelial-mesenchymal transition and
blocking senescence. Hum Pathol. 45:1839–1846. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang T, Li Y, Tuerhanjiang A, et al:
Twist2 contributes to cisplatin-resistance of ovarian cancer
through the AKT/GSK-3beta signaling pathway. Oncol Lett.
7:1102–1108. 2014.PubMed/NCBI
|
|
25
|
Wang SW, Liu SC, Sun HL, et al: CCL5/CCR5
axis induces vascular endothelial growth factor-mediated tumor
angiogenesis in human osteosarcoma microenvironment.
Carcinogenesis. 36:104–114. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu XW, Wu TY, Yi X, et al: Prognostic
significance of VEGF expression in osteosarcoma: A meta-analysis.
Tumour Biol. 35:155–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou Q, Zhu Y, Deng Z, Long H, Zhang S and
Chen X: VEGF and EMMPRIN expression correlates with survival of
patients with osteosarcoma. Surg Oncol. 20:13–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen D, Zhang YJ, Zhu KW and Wang WC: A
systematic review of vascular endothelial growth factor expression
as a biomarker of prognosis in patients with osteosarcoma. Tumour
Biol. 34:1895–1899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu SM, Yu L, Tian JJ, et al: Twist
modulates lymphangiogenesis and correlates with lymph node
metastasis in supraglottic carcinoma. Chin Med J (Engl).
124:1483–1487. 2011.PubMed/NCBI
|
|
30
|
Che N, Zhao XL, Sun T, et al: The role of
Twist1 in hepatocellular carcinoma angiogenesis: A clinical study.
Hum Pathol. 42:840–847. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dalal S, Berry AM, Cullinane CJ, et al:
Vascular endothelial growth factor: A therapeutic target for tumors
of the Ewing's sarcoma family. Clin Cancer Res. 11:2364–2378. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kaya M, Wada T, Kawaguchi S, et al:
Increased pre-therapeutic serum vascular endothelial growth factor
in patients with early clinical relapse of osteosarcoma. Br J
Cancer. 86:864–869. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oda Y, Yamamoto H, Tamiya S, et al: CXCR4
and VEGF expression in the primary site and the metastatic site of
human osteosarcoma: Analysis within a group of patients, all of
whom developed lung metastasis. Mod Pathol. 19:738–745. 2006.
View Article : Google Scholar : PubMed/NCBI
|
